ClinicalTrials.gg
Not yet recruitingNCT07423104Updated Oct 16, 2026

A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia

A Phase 2 interventional study of CAV in Acute Myeloid Leukemia (AML), sponsored by University of Rochester. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Leukemia, Myeloid, Acute by University of Rochester — 5 open to participants now, 5 under way, none of them phase 3. Leukemia, Myeloid, Acute · University of Rochester.

Planned enrollment
7th of 12
24 · median 26
Started
2026
with 1 other
Phase 2
2 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Acute by University of Rochester, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 13th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

5 of the 14 studies in Leukemia, Myeloid, Acute by University of Rochester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leukemia, Myeloid, Acute by University of Rochester, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is a bone marrow cancer that is challenging to treat. It is the most common type of acute leukemia, particularly in adults. There are around 20,000 cases of acute myeloid leukemia diagnosed in the United States every year. Despite the recent significant progress in the understanding of acute myeloid leukemia leading to the development of new therapies, significant challenges remain. The initial treatment for acute myeloid leukemia involves using therapies aimed at reducing the disease burden in the bone marrow to the lowest possible level (a state known as disease remission). This is usually followed by consolidation treatment aimed at curing the disease. The initial treatment involves high intensity chemotherapy in younger adults who can tolerate these therapies and low intensity therapies for older adults or those with other medical conditions that prohibit them from receiving high intensity chemotherapy. The consolidation therapy involves either more chemotherapy or a bone marrow transplant. In the recent years, a treatment regimen consisting of two drugs; Azacytidine and Venetoclax has become the standard of care for low intensity therapy intended for older adults. Despite significant improvement in outcomes of acute myeloid leukemia in older adults after the introduction of Azacytidine/Venetoclax, yet 40% of patients who receive this treatment will either be refractory to it or relapse after an initial remission. Those whose leukemia relapses after Azacytidine/Venetoclax treatment are left with very few treatment options and have a dismal prognosis. Based on previous laboratory studies, certain subtypes of acute myeloid leukemia tend to not respond as well to Azacytidine/Venetoclax therapy and have a better chance of responding to the treatment regimen the investigators are proposing in this study. The study treatment regimen consists of 3 drugs; Cladribine, low dose Cytarabine and Venetoclax. Demonstrating efficacy of the study regimen in treatment of relapsed/refractory acute myeloid leukemia, after prior Venetoclax therapy, will provide another treatment option for those with a relapsed/refractory disease who wish to continue receiving therapy.

Read the detailed description

Among the main mechanisms implicated in acute myeloid leukemia (AML) relapse after treatment with Venetoclax is upregulation of myeloid cell leukemia 1 (MCL-1) in AML cells with their survival becoming less dependent on the Venetoclax target, B-cell leukemia/lymphoma 2 (BCL-2). Leukemic stem cells (LSCs) in AML with monocytic differentiation are significantly more resistant to treatment with azacytidine/venetoclax being less dependent on BCL-2 and demonstrating preferential reliance on MCL-1 for survival. Cladribine, combined with Venetoclax in preclinical studies have shown efficacy in overcoming resistance to Venetoclax by downregulating MCL-1, particularly in AML with monocytic features and/or rat sarcoma oncogene (RAS) mutations.

The investigators propose to use the cladribine, low-dose cytarabine and venetoclax (CAV) regimen in patients with relapsed/refractory or secondary AML (transformed from myelodysplastic syndrome [MDS], myeloproliferative neoplasm [MPN] or MDS/MPN overlap) who were previously treated with a venetoclax-containing regimen, whose disease lacks molecular targets with approved therapies. CAV is a medium intensity regimen that has demonstrated acceptable safety and tolerability in older patients with AML and/or those who are unfit for intensive therapies

Objective:

The primary objective is to estimate the rate of composite complete remission (CRc) in participants with relapsed/refractory or secondary AML who are treated with cladribine, low-dose cytarabine and venetoclax after prior treatment with a venetoclax-containing regimen.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • acute myeloblastic leukemia
  • acute myelocytic leukemia
  • relapse
  • acute myelogenous leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with AML (according to European LeukemiaNet 2022 Criteria) after treatment with a Venetoclax-containing regimen.

    • Participants with MDS, MPN, or MDS/MPN overlap who develop secondary AML after treatment with a Venetoclax-containing regimen.
    • Prior therapy with hydroxyurea or emergency use of Cytarabine (up to 1 gm total dose) for cytoreduction is allowed.
    • Prior hematopoietic stem-cell transplant () and/or donor lymphocyte infusion (DLI) are allowed if at the time of relapse ≥ 90 days have passed from the date of the last stem cell transplant (90-day duration not required for DLI).
    • Age ≥ 18 years old.
    • Eastern Oncology Group () performance status of ≤ 2
    • Participants must agree to take the following reproductive precautions:

      • Negative urine pregnancy test within one week prior to starting the study therapy for all women of .
      • Participants who could become pregnant should use effective during therapy and for 6 months after the last dose of study treatments. Participants with partners who could become pregnant should also use effective contraception during therapy and for 6 months after the last dose of study treatments.
      • Nursing women should discontinue breastfeeding during therapy and for 10 days after the last dose of study treatments.
    • Adequate organ function as follows:

      • liver function ( \< 2mg/dL, and/or ALT \<3 x ). Unless liver enzyme abnormalities are suspected by the treating investigator to be due to leukemic infiltration after discussion with the principal investigator (PI).
      • kidney function (creatinine \< 1.5 x ULN)
    • Ability to understand the study procedures and requirements. A signed by the participant or an authorized legal representative is required.

Exclusion criteria

  • Pregnant or breastfeeding women

    • Uncontrolled active infections, i.e., signs of severe sepsis or hemodynamic instability
    • Concurrent diagnosis with another active (indolent or adequately treated malignancies are allowed after discussion with the PI.
    • Decompensated organ failure
    • Documented to any of the study treatments
    • Participants with a diagnosis of acute promyelocytic leukemia (APL)
    • Recipients of previous who have > grade 1 (GVHD) of the gastro-intestinal tract, liver, lung or skin.
    • Prior therapy with purine analogues (Fludarabine, Clofarabine or Cladribine) unless it was part of a prior HSCT conditioning regimen.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm 1

    cladribine, low-dose cytarabine, venetoclax.

    Drug: CAV

Interventions

  • DrugCAV

    cladribine 5 mg/m2 intravenous infusion daily on days 1-5, cytarabine 20 mg/m2 subcutaneous injection once daily on days 1-10, venetoclax 400 mg oral daily days 1-21.

06

What researchers measure

Primary outcomes

  1. Composite complete remission

    Best response of complete remission, complete remission with incomplete hematologic recovery or morphologic leukemia-free state after 2 cycles of treatment.

    Time frame: Response assessment will be done once at the end of cycle 1 and once at the end of cycle 2 (each cycle is 28 days).

Other outcomes

  1. Patient reported outcomes

    Evaluation of impact of the study regimen on the quality of life of the study participants by asking the study participants to fill in the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30). All of the questionnaire scales range in score from 0 (Worst) to 100 (Best).

    Time frame: Once before study treatments and once at the end of cycle 2 of treatment or earlier if the participant goes off the study before the end of cycle 2 (each cycle is 28 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 Sep 6;13(9):2032-2049. doi: 10.1158/2159-8290.CD-22-1297. PubMed 37358260 ↗
  • Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 Nov 20;40(33):3848-3857. doi: 10.1200/JCO.21.02823. Epub 2022 Jun 15. PubMed 35704787 ↗
  • Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962. No abstract available. PubMed 38546692 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2029, 25 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 25 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 20, 2026
StartEst.
Dec 31, 2026was Aug 2026
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 1, 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 15, 2026→Dec 31, 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Aug 15, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07423104
Responsible party
Bassil Botros (Assistant Professor of Medicine, University of Rochester) — Principal investigator
First posted
Feb 20, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 1, 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Bassil Botros, MD
Contact
bassil_botros@urmc.rochester.edu
585-275-5863
Wilmot Clinical Trials Office
Contact
wcictoresearch@urmc.rochester.edu
585-275-5863

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion